Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Takeda California Inc.

Division of Takeda Pharmaceutical Co. Ltd.
takedacalifornia.com

Latest From Takeda California Inc.

Sea Lane Biotechnologies LLC

Sea Lane Biotechnologies LLC’s original goal was to leverage the immunological repertoire of flu epidemic survivors by harvesting bone marrow and screening for natural antibodies that could then be developed into drugs, but the human-derived antibodies that Sea Lane gathered in its early days contributed to a new technology platform. Sea Lane thinks its technology, called ConCIRT, for Contextual Immune Repertoire Technology, will prove capable of generating novel treatments for cancer and potentially other non-infectious diseases.

BioPharmaceutical Platform Technologies

Deals Shaping The Medical Industry, July 2013

Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing.

BioPharmaceutical Medical Device

Deals Shaping The Medical Industry, December 2012

Derived from Strategic Transactions, EBI’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment –In Vitro Diagnostics, Medical Devices, and Pharmaceuticals– and then categorized by type –Acquisition, Alliance, or Financing.

BioPharmaceutical Medical Device

Takeda’s Strategic Run Up To Nycomed

With the acquisition of Nycomed, Takeda’s long-standing strategy for becoming a world-class pharma has come into focus. The company spent much of the past decade building up its pipeline, globalizing R&D and importing Western staff, assets, platforms and processes. It also began a hectic period of M&A unparalleled among Japanese companies, culminating in 2011 with its acquisition of Nycomed. Now its focus will need to shift from big acquisitions and organizational makeover to execution.

BioPharmaceutical Business Strategies
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Research, Analytical Equipment & Supplies
  • Therapeutic Areas
  • Cancer
  • Inflammation
  • Metabolic Disorders
  • Alias(es)
  • Syrrx Inc.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Takeda Pharmaceutical Co. Ltd.
  • Senior Management
  • Keith P Wilson, PhD, Pres. & CSO
    Umi Chong, Sr. Dir., Fin.
  • Contact Info
  • Takeda California Inc.
    Phone: (858) 622-8528
    10410 Science Center Dr.
    San Diego, CA 92121
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register